Use outside of clinical trials or approved indications is illegal in many jurisdictions
Some prescribers recommend longer gaps, particularly for patients switching from higher semaglutide doses
#Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare @hvanspall @DrMarthaGulati @AndrewJSauer @Hragy @AnastasiaSMihai @almucastro01 @mmamas1973 @biljana_parapid @brendonneuen academic.oup.com/ndt/advance-ar Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial Semaglutide reduced risks of infection SAEs, hospitalization due to infection, and all-cause death with greater benefit among those with poorer glycemic control and greater baseline albuminuria
Healthcare providers may refer to this condition as TMAU or fish odor syndrome
Pharmacol Rev 67:564600 Del Prato S, Kahn SE, Pavo I et al (2021) Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Therefore, further study is needed to establish their efficacy in the clinically relevant therapeutic models
.png)
